STRUCTURED ABSTRACT
Introduction Metabolic disorders are risk factors for Alzheimer’s disease (AD), although underlying mechanisms remain unclear. We investigated the relationship between peripheral metabolic markers – adiponectin, FGF-21 and IGFBP-2 – and AD.
Methods Participants with subjective cognitive decline (SCD), mild cognitive impairment (MCI), AD and cognitively healthy controls (CH) were from the CIMA-Q cohort (n=287). Serum adiponectin, FGF-21, and IGFBP-2 concentrations were measured, compared between groups, and assessed for associations with clinical, cognitive, biochemical and MRI data.
Results Metabolic dysfunction was linked to lower adiponectin and IGFBP-2, but higher FGF-21. Both FGF-21 and IGFBP-2 increased with age and were inversely associated with cognitive performance. IGFBP-2 was elevated at SCD stage and correlated with plasma pTau181 and amygdala atrophy. Adiponectin was unrelated to cognition.
Discussion These findings suggest that IGFBP-2, and FGF-21 to a lesser extent, may serve as early biomarkers of cognitive impairment, reflecting intricate links between peripheral dysmetabolism and AD.
Competing Interest Statement
H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of CERimmune Therapeutics (outside submitted work). The other authors report no conflict of interest.
Funding Statement
This research project was financially supported by grants to F.C. from the Canadian Institutes of Health Research (PJT-183735 and ENG-179033), Canadian Consortium on Neurodegeneration in Aging (CAN 163902) and the Quebec Network for Aging (pilot grant 2018/2019; jointly led by F.C. and M.T.). The Consortium for the Early Identification of Alzheimer's Disease - Quebec (CIMA-Q) received funding from the Fonds d'Innovation Pfizer-FRQS for Alzheimer's disease and related diseases, FRQS, RQRV (Quebec Network for Research on Aging), Fondation Courtois (Neuromod project) and the Fondation Famille Lemaire. C.D.T. is supported by a Phase 1 FRQS/MSSS Training Scholarship for Specialized Medical Residents Pursuing a Research Career from the Fonds de recherche du Quebec - Sante (#335164) and, at the time of the study, a Fondation Famille Lemaire's Postdoctoral Scholarship for the Consortium for the Early Identification of Alzheimer's Disease - Quebec (CIMA-Q). J.V. was supported by a Fondation Famille Lemaire's studentship. H.Z. is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356, #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, and Swedish State Support for Clinical Research (#ALFGBG-71320).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Aging-Neuroimaging Research Ethics Committee of the CIUSSS du Centre-Sud-de-Ile-de-Montreal (CER VN 14-15-19 and CER VN 18-19-01) and the Research Ethics Committee of the CHU du Quebec Research Center (2015-2366, 2019-4458, 2019-4460 and 2022-6290) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
